Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by palinc2000on Feb 27, 2022 3:40pm
123 Views
Post# 34465973

RE:Marsolais said ´300 is a VERY GOOD dose

RE:Marsolais said ´300 is a VERY GOOD dose

More ftom the transcripts
 

Okay, on TH1902, again, how serious were the adverse events in the cycles after the initial cycle?

Paul Levesque

Christian?

Christian Marsolais

Yeah, what we've seen is our adverse events are linked to when you get a higher dose of docetaxel. At some point you get [indiscernible] or go higher to a certain level. And what you see with docetaxel, they seem the same after two or three cycles. That's what the signs of neurotoxicity that's seen with those docetaxel. We've seen also some signs on visual acuity seen with docetaxel and some fatigue. Then we have regular discussion with all of the investigator taking part in this study on based on that observation, we decided to build to this 300 mg/m2 where we think that even if it's at 1.5 times a dose of docetaxcel, it will be much better tolerated and will be able to give way more cycle, a the 200 mg/m2, which is the objective in treating advanced cancer patients.


palinc2000 wrote: Here are his exact words from the transcripts

 

Christian Marsolais

Yeah, what we mentioned is that we have seen some monthly DLT [indiscernible] in 420 mg/m2. We reduced the dose to 300 20 mg/m2, which is 1.5 times the dose of docetaxel but given were administered alone, then this is a very good dose. And now we're proceeding with this study enrolling three patients looking at DLT and is following three patients. After that, we'll be ready to open the basket trial. At this stage, based on the data that we have, we're not expecting any DLTs of 300 but that will be known in the next two, three months.



<< Previous
Bullboard Posts
Next >>